Tezepelumab Treatment in Korean Severe Asthma Patients

NCT06438913 | Not Yet Recruiting FDA Drug

• 1 other identifier: 2024-0215
• Study Type: observational
• Target: 100
• Locations: 0 countries
• Sites: N/A

Brief Summary

There is no study that systematically evaluated the effect of Tezepelumab on cough, and based on this background, the present researchers aimed to evaluate the effect of Tezepelumab treatment in patients with severe asthma who complain of cough using the Leicester Cough Questionnaire, a cough-related quality of life measurement tool.

Conditions

Asthma

Outcome Measures

Primary Outcomes (1)

• Effects of Tezepeluma on Cough

  The effectiveness of Tezepelumab on cough was assessed by comparing the LCQ score at 1 and 12 months of administration with the LCQ score at the time of registration.

  1years

Interventions

Tezepelumab DRUG

Tezepelumab blocks thymic stromal lymphopoietin (TSLP), an epithelial cytokine suggested to be important in the initiation and continuation of airway inflammation.

Eligibility Criteria

• Age: 19 Years - 79 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

1)

You may qualify if:

• Severe asthma patients aged 19 or older and 79 or younger
• Cases diagnosed as asthma by an expert and classified as severe asthma according to the 2014 ATS/ERS guidelines
• \- Patients who require the use of high-dose inhaled steroids and additional control agents or systemic steroids for more than 50% of the year to control symptoms. Or, if asthma is not controlled even with the medication. Here, uncontrolled asthma means that any one of the following is satisfied.
• ACT score less than 20 or 'not well controlled' according to GINA guideline
• frequent exacerbations; Requires systemic steroid administration (over 3 consecutive days) more than twice in the previous year If you did
• severe exacerbation; A condition that required hospitalization, admission to an intensive care unit, or application of a ventilator in the previous year If you have been angry at least once
• airflow restrictions; FEV1 \< 80%
• If a cough is due to asthma according to a doctor and the cough onset scale (cough visual analogue scale, cough VAS) satisfies 30 or more points out of 100.
• If a positive result is confirmed in the methacholine (or mannitol) bronchial challenge test (if the bronchial challenge test result is not available or the test is difficult to proceed, it can be replaced with a positive bronchodilator response test)

You may not qualify if:

• Minors under 19 years of age, senior citizens over 79 years of age
• If there is a history of use of other biological agents within 3 months prior to study registration
• Cases where there was an acute exacerbation requiring a steroid burst (total 90mg prednisolone or more) during the 4-week screening period before study registration (possible for long-term prednisolone users)
• Cases accompanied by clinically serious respiratory disease in addition to severe asthma
• When accompanied by hypereosinophilic syndrome, ABPA, EGPA
• When it is difficult to evaluate asthma alone due to severe respiratory disease
• Pregnant women

Sponsors & Collaborators

• Asan Medical Center: lead

MeSH Terms

Conditions

Asthma

Interventions

tezepelumab

Condition Hierarchy (Ancestors)

Bronchial Diseases; Respiratory Tract Diseases; Lung Diseases, Obstructive; Lung Diseases; Respiratory Hypersensitivity; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Target Duration: 1 Year
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: May 17, 2024
• First Posted: June 3, 2024
• Study Start: June 12, 2024
• Primary Completion: May 12, 2025
• Study Completion (Estimated): December 31, 2026
• Last Updated: June 3, 2024

Record last verified: 2024-05